Abcellera Biologics Inc
ABCL4.480USD
+0.580+14.87%
Fechamento 07/18, 16:00（ET）Cotações atrasadas em 15 min
1.34BValor de mercado
PerdaP/L TTM
Mais detalhes de Abcellera Biologics Inc Empresa
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Informações da empresa
Código da empresaABCL
Nome da EmpresaAbcellera Biologics Inc
Data de listagemDec 11, 2020
Fundado em2012
CEODr. Carl L.G. Hansen, Ph.D.
Número de funcionários596
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 11
Endereço150 W 4Th Avenue
CidadeVANCOUVER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísCanada
Código postalV5Y 1G6
Telefone16045599005
Sitehttps://www.abcellera.com/
Código da empresaABCL
Data de listagemDec 11, 2020
Fundado em2012
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Dr. Michael R. Hayden, M.B. Ch.B., Ph.D.
Dr. Michael R. Hayden, M.B. Ch.B., Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Detalhamento da receita
Moeda: USDAtualizado em: sáb, 22 de fev
Moeda: USDAtualizado em: sáb, 22 de fev
FY2024Q2
FY2023Q2
Por EmpresaUSD
Nome
Receita
Proporção
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
Distribuição de ações
Atualizado em: há 17 horas
Atualizado em: há 17 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Thermopylae Holdings Ltd
18.81%
Baker Bros. Advisors LP
9.22%
Capital Research Global Investors
4.48%
Capital World Investors
4.48%
Baillie Gifford & Co.
3.75%
Other
59.27%
Investidores
Investidores
Proporção
Thermopylae Holdings Ltd
18.81%
Baker Bros. Advisors LP
9.22%
Capital Research Global Investors
4.48%
Capital World Investors
4.48%
Baillie Gifford & Co.
3.75%
Other
59.27%
Tipos de investidores
Investidores
Proporção
Corporation
18.81%
Investment Advisor
18.34%
Hedge Fund
15.01%
Investment Advisor/Hedge Fund
6.74%
Individual Investor
4.16%
Bank and Trust
1.77%
Private Equity
1.42%
Venture Capital
0.47%
Research Firm
0.46%
Other
32.83%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
368
202.15M
67.73%
-13.96M
2025Q1
429
202.31M
67.85%
-22.54M
2024Q4
453
194.86M
65.41%
-21.40M
2024Q3
451
190.45M
64.55%
-29.37M
2024Q2
449
195.17M
66.27%
-23.48M
2024Q1
442
202.34M
69.21%
-22.49M
2023Q4
434
206.18M
71.07%
-38.61M
2023Q3
437
216.53M
74.89%
-39.50M
2023Q2
439
222.03M
76.83%
-29.38M
2023Q1
423
223.82M
78.22%
-38.92M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Thermopylae Holdings Ltd
56.14M
18.81%
--
--
Apr 01, 2025
Baker Bros. Advisors LP
27.53M
9.22%
--
--
Mar 31, 2025
Capital World Investors
13.36M
4.48%
+5.43M
+68.41%
Mar 31, 2025
Baillie Gifford & Co.
11.20M
3.75%
-1.04M
-8.50%
Mar 31, 2025
Voya Investment Management LLC
10.62M
3.56%
--
--
Mar 31, 2025
Lecault (Veronique)
9.61M
3.22%
--
--
Apr 01, 2025
UBS Asset Management (Switzerland)
9.06M
3.04%
+4.56M
+101.35%
Mar 31, 2025
UBS Asset Management (Americas) LLC
6.61M
2.21%
+6.61M
--
Mar 31, 2025
Two Sigma Investments, LP
5.77M
1.93%
-94.12K
-1.60%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
1.74%
Virtus LifeSci Biotech Clinical Trials ETF
1.02%
TrueShares Technology, AI & Deep Learning ETF
0.7%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.07%
SPDR S&P International Small Cap ETF
0.07%
iShares Biotechnology ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
Invesco RAFI Developed Mkts ex-US SM ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção1.74%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.02%
TrueShares Technology, AI & Deep Learning ETF
Proporção0.7%
ProShares Ultra Nasdaq Biotechnology
Proporção0.12%
Invesco Nasdaq Biotechnology ETF
Proporção0.07%
SPDR S&P International Small Cap ETF
Proporção0.07%
iShares Biotechnology ETF
Proporção0.05%
Avantis US Small Cap Equity ETF
Proporção0.01%
Invesco RAFI Developed Mkts ex-US SM ETF
Proporção0.01%
SPDR Portfolio Developed World ex-US ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
